peptideInjectableNot FDA-approvedResearch chemicalNot FDA-approved for any indication; sold in some markets as a research peptide with no established human clinical trial recordOriginates from a Russian gerontology research program studying short bioregulator peptides; the cited papers are preclinical and mechanistic, not clinical dosing studies
VesugenBenefits, Dosage & Interactions
Vesugen is a synthetic peptide, identified by the amino acid sequence lysine-glutamic acid-aspartic acid (Lys-Glu-Asp). It belongs to a class of synthetic peptides designed to mimic the actions of naturally occurring bioregulators. Research on Vesugen focuses on healthy aging. Vesugen is administered by injection rather than orally.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
Not reported in the cited literature
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- No standardized human dosing exists in the peer-reviewed record; cited studies used peptide preparations in cell-culture and animal models, not defined per-kilogram human doses[1][2][3]
Reported for Vesugen in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Vesugen entry is written from. Each number matches an inline marker above.
- [1]Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndromeMeshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE · Advances in Gerontology (Uspekhi Gerontologii) · 2015 · Peer-reviewed · PMID 26390612
- [2]Investigation of antihypoxic properties of short peptidesKozina LS · Advances in Gerontology (Uspekhi Gerontologii) · 2008 · Peer-reviewed · PMID 18546825
- [3]Peptides tissue-specifically stimulate cell differentiation during their agingKhavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM · Bulletin of Experimental Biology and Medicine · 2012 · Peer-reviewed · PMID 22808515
How to track Vesugen doses
Vesugen is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Vesugen is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Vesugen comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
Review Vesugen alongside your logged metrics and any relevant blood work every few weeks before changing the dose, so the change is a response to data rather than to a good or bad day.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
What is Vesugen studied for?
What is Vesugen?
Vesugen is a synthetic peptide, identified by the amino acid sequence lysine-glutamic acid-aspartic acid (Lys-Glu-Asp). It belongs to a class of synthetic peptides designed to mimic the actions of naturally occurring bioregulators. Research into Vesugen primarily focuses on its potential role in regulating elements of the vascular system. This peptide is not a vitamin, mineral, or conventional drug, but rather a compound under scientific investigation for its potential biological activities, particularly concerning circulatory health. Its development stems from a line of research exploring short peptides as potential therapeutic or prophylactic agents. Vesugen is typically administered via injection in research settings, with a relatively short half-life of approximately one hour, meaning it is quickly processed by the body. As an investigational compound, its precise mechanisms and effects are still being elucidated, and it is not approved for medical use outside of research contexts. (PubChem, DrugBank)
What does the research say about Vesugen?
Tap a section to expand.
The proposed mechanism of action for Vesugen involves its interaction with the vascular endothelium. Endothelial cells line the interior surface of blood vessels and play a crucial role in vascular tone, blood clotting, and inflammatory responses. Though specific receptor interactions are still under investigation, it is hypothesized that Vesugen may exert its effects by modulating endothelial cell function, potentially influencing processes such as blood vessel permeability, cellular repair, and overall vascular integrity. This modulation is thought to occur through direct binding or signaling pathways that impact gene expression or protein synthesis within these cells. The short amino acid sequence (Lys-Glu-Asp) is believed to be key to its interaction with specific biological targets. Further research is ongoing to fully characterize the molecular pathways through which Vesugen may exert its observed or hypothesized biological effects. (PubChem, research literature review)
Research into Vesugen has explored several potential areas of benefit, primarily centered around vascular health. Studies have investigated its effects on microcirculation and the integrity of blood vessel walls. Some preclinical research suggests that Vesugen may contribute to maintaining the functional state of the vascular system. These observations are based on experimental models and do not represent confirmed clinical benefits in humans. The concept behind these investigations is that by supporting endothelial function, the peptide could contribute to the overall health of the circulatory system. However, it is crucial to emphasize that these are preliminary findings from experimental research, and further robust clinical trials are necessary to establish any definitive benefits in human populations. (Research literature, observational studies)
The evidence supporting Vesugen's effects is primarily derived from preclinical studies and early investigational research. These studies often utilize animal models or in vitro cellular systems to explore the peptide's biological activity. For instance, some research has examined its impact on blood flow parameters and vascular permeability in experimental settings. While such studies provide foundational insights into potential mechanisms and applications, they are not directly transferable to human clinical outcomes. Controlled human trials are limited, and as such, there is no extensive body of robust, peer-reviewed clinical evidence demonstrating efficacy or safety in humans for any specific condition or health goal. The scientific community is currently evaluating Vesugen as a subject of ongoing research, and comprehensive data from large-scale human studies are required to validate any claimed benefits. (Research literature, PubChem reviews)
Given that Vesugen is an investigational peptide, the full spectrum of potential side effects in humans is not yet well-established. Based on its peptide nature and preclinical observations, common side effects associated with injectable peptides or similar compounds might include localized reactions at the injection site, such as pain, redness, swelling, or itching. Systemic side effects, while not extensively documented in humans, could theoretically involve transient physiological changes. However, without comprehensive clinical trial data, a definitive list of adverse reactions or their frequency and severity cannot be provided. Individuals considering any investigational compound should be aware of the inherent uncertainties regarding safety. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Vesugen is an experimental compound not approved for clinical use. Due to the limited human data, there are significant unknowns regarding its long-term safety, potential drug interactions, and effects in diverse populations (e.g., pregnant or lactating individuals, children, elderly, or those with pre-existing medical conditions). Individuals with compromised immune systems or those on anticoagulant medications should exercise extreme caution due to theoretical risks that have not been fully explored. The potential for allergic reactions, though unquantified, should also be considered, as with any novel peptide. Self-administration of unapproved compounds carries inherent risks. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to the investigational status of Vesugen and the lack of comprehensive clinical data, specific contraindications have not been definitively established. However, based on general pharmacological principles and the nature of investigational compounds, it is strongly advised that Vesugen should not be used by pregnant or breastfeeding individuals, children, or individuals with severe renal or hepatic dysfunction, autoimmune disorders, or a history of hypersensitivity to peptides. Anyone undergoing treatment for cardiovascular conditions, bleeding disorders, or cancer should avoid Vesugen until extensive safety data are available and under strict medical supervision due to theoretical interactions or exacerbation of conditions. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to its investigational status, there is insufficient data to definitively list compounds that should not be mixed with Vesugen. However, because its proposed mechanism involves vascular effects, caution is warranted when combining it with medications influencing blood pressure, blood clotting, or endothelial function. This includes, but is not limited to, anticoagulants (e.g., warfarin, heparin), antiplatelet drugs (e.g., aspirin, clopidogrel), vasodilators, and certain anti-inflammatory agents. Combining Vesugen with other experimental peptides or unapproved substances is also strongly discouraged due to unknown synergistic or antagonistic effects. The potential for unexpected interactions with herbs, supplements, or prescription medications is high due to the lack of specific research. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Vesugen is typically administered at any time of day in research settings, as its half-life is approximately one hour, meaning it is quickly metabolized. The efficacy or safety is not known to be specifically influenced by food intake, although some research protocols may stipulate administration either with or without food. As a short-acting peptide, frequent administration may be necessary to maintain consistent levels, depending on the research objectives. Dose is user-directed and must be set by a licensed clinician. (Research protocols, DrugBank)
What interacts with Vesugen?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Vesugen
Vesugen is a synthetic tripeptide (Lys-Glu-Asp) developed for its potential effects on the vascular system. It is an investigational compound, not an approved medication.
In research settings, Vesugen is typically administered via injection.
No, Vesugen is an investigational compound and is not approved by regulatory bodies for medical use in humans outside of specific research protocols.
Preclinical research suggests potential roles in supporting vascular health and microcirculation, but these findings have not been confirmed in human clinical trials.
Comprehensive human safety data are limited. Potential side effects might include injection site reactions. The full range of possible adverse effects is not yet established.
Interaction risk for Vesugen comes from the rest of the stack: other peptides, prescription medicines, hormone therapy and peptides. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Vesugen with no sign-up.
Vesugen is administered by injection, so the measured volume — not a tablet count — is the unit that matters. Published ranges differ between studies and formulations — the dose to use is the one on your label or from your clinician.
There is no single answer for Vesugen plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Vesugen with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Vesugen varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Vesugen depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Vesugen the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Verify at
Publisher search links for Vesugen. These are places to check the information — they are not citations, so they are not numbered.
- PubChem(publisher search, opens in a new tab)National Center for Biotechnology Information · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Vesugen?
Plain-text summary, safe to quote verbatim:
Vesugen is a synthetic peptide, identified by the amino acid sequence lysine-glutamic acid-aspartic acid (Lys-Glu-Asp). It belongs to a class of synthetic peptides designed to mimic the actions of naturally occurring bioregulators. Research on Vesugen focuses on healthy aging. Vesugen is administered by injection rather than orally.
Source: DoseRoutine — https://doseroutine.com/library/vesugen
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Vesugen — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/vesugen
What compounds are similar to Vesugen?
Others in the peptide category or studied for the same goals.
Which goals is Vesugen used for?
Other compounds studied for the same benefits as Vesugen.
Continue exploring
See every compound DoseRoutine catalogs for these goals.